Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subjects will consist of ambulatory males and females, 50-75 years of age, of any race, diagnosed with hypertension (diagnosis made over 6 months), and echocardiographic evidence of grade I or II diastolic dysfunction.~* There is no need for standardization of hypertension treatment, as we select only patients who have diastolic dysfunction during treatment.~Exclusion Criteria:~* Unstable angina or myocardial infarction in the past 3 months.~* Biochemical evidence of renal or hepatic failure.~* Severe anemia: defined as hemoglobin level less than 7 g/dL.~* Current cancer or other major illness not associated with the heart.~* Bleeding disorders.~* Taking anticoagulants including low dose aspirin.~* Diabetes.~* Known allergy to Pycnogenol.~* Being pregnant or breastfeeding.~* Systolic blood pressure over 180 mmHg or less than 100 mmHg, and Diastolic blood pressure over 110 mmHg or less than 50 mmHg.~* Current smoking.~* Having breast implants.~* Taking any of the following: birth control products, Diethylstilbestrol, Ephedra, ephedrine, or pseudoephedrine (except where used in prescription products), hormone replacement products, Isotretinoin, any product containing mercury, Phentermine in combination with fenfluramine (including but not limited to Pondimin) or dexfenfluramine (Redux).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pycnogenol (Type: EXPERIMENTAL): 200 mg/day
- Control (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).